For the first time, scientists have charted the activation of gut-based T cells in multiple sclerosis using two-photon imaging in a mouse model. Further, that activation appears to be microbiome-dependent.
For the first time, scientists have charted the activation of gut-based T cells in multiple sclerosis using two-photon imaging in a mouse model. Further, that activation appears to be microbiome-dependent.
Non-Hispanic White people have the largest prevalence of multiple sclerosis of any racial group in the United States, followed by non-Hispanic Black individuals, according to a population-based cohort study published in JAMA Neurology.
Non-Hispanic White people have the largest prevalence of multiple sclerosis of any racial group in the United States, followed by non-Hispanic Black individuals, according to a population-based cohort study published in JAMA Neurology.
Patients with multiple sclerosis undergoing fertility treatments were not found to be at an elevated relapse risk following treatment, according to a study published in Neurology Neuroimmunology & Neuroinflammation.
Patients with multiple sclerosis undergoing fertility treatments were not found to be at an elevated relapse risk following treatment, according to a study published in Neurology Neuroimmunology & Neuroinflammation.
Stressors experienced across the lifespan, including poverty, abuse, and divorce, have been linked with worse health and functional outcomes for people living with multiple sclerosis (MS).
Stressors experienced across the lifespan, including poverty, abuse, and divorce, have been linked with worse health and functional outcomes for people living with multiple sclerosis (MS).
A pro-inflammatory diet is associated with a higher relapse risk and more inflammatory brain lesions in multiple sclerosis (MS) patients. Results from the prospective cohort study were published in the Multiple Sclerosis Journal.
A pro-inflammatory diet is associated with a higher relapse risk and more inflammatory brain lesions in multiple sclerosis (MS) patients. Results from the prospective cohort study were published in the Multiple Sclerosis Journal.
For the treatment of relapsing-remitting multiple sclerosis (MS), a new study has found the comparative clinical effectiveness of autologous hematopoietic stem cell transplant (AHSCT) superior to other DMTs.
For the treatment of relapsing-remitting multiple sclerosis (MS), a new study has found the comparative clinical effectiveness of autologous hematopoietic stem cell transplant (AHSCT) superior to other DMTs.
A patient’s age at discontinuation of first-line disease-modifying therapy (DMT) was a significant predictor of the return of inflammatory disease activity and relapse among patients with multiple sclerosis (MS), according to study results...
A patient’s age at discontinuation of first-line disease-modifying therapy (DMT) was a significant predictor of the return of inflammatory disease activity and relapse among patients with multiple sclerosis (MS), according to study results...
Women with multiple sclerosis (MS) who underwent fertility treatment did not exhibit an elevated risk of MS relapse following their treatment, according to results from a multicenter cohort analysis.
Women with multiple sclerosis (MS) who underwent fertility treatment did not exhibit an elevated risk of MS relapse following their treatment, according to results from a multicenter cohort analysis.
Patients with progression independent of relapse activity (PIRA) within 5 years of multiple sclerosis diagnosis had a 26-fold higher risk of developing severe disability compared with patients with PIRA late in the disease.
Patients with progression independent of relapse activity (PIRA) within 5 years of multiple sclerosis diagnosis had a 26-fold higher risk of developing severe disability compared with patients with PIRA late in the disease.
The findings suggest patient-reported outcome measures provide valuable information on the well-being of patients with multiple sclerosis, researchers said.
The findings suggest patient-reported outcome measures provide valuable information on the well-being of patients with multiple sclerosis, researchers said.
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click